Full text is available at the source.
Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions
How Glucagon-Like Peptides and Their Receptor Activators Help Manage Heart, Kidney, and Metabolic Conditions
AI simplified
Abstract
GLP-1 receptor agonists are established therapies that improve glycemia and reduce cardiovascular and kidney risks.
- GLP-1 receptor agonists were initially developed for managing type 2 diabetes but have shown broader benefits.
- Large clinical trials confirm their effectiveness in achieving and maintaining weight management goals.
- These therapies are associated with a reduction in cardiovascular and kidney risks.
- Early evidence indicates that the dual GIP/GLP-1 receptor agonist tirzepatide may offer similar advantages.
AI simplified